Invitation to presentation of Q-linea’s Interim report Q3-2020 on November 5, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – September 2020 on Thursday, November 5, 2020 at 07:30 a.m. CET.

Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on November 5, 2020, at 1:00 – 2:00 p.m CET.

Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q3 interim report followed by a Q&A-session.

 

To participate, please call any of the following phone numbers from:

Sweden: + 46 8 566 427 04

UK: + 44 333 300 9268

US: + 1 833 249 8403
 

Webcast: https://tv.streamfabriken.com/q-linea-q3-2020
 
For more information, please contact:

Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0)70-600 15 20

 
The information was submitted for publication, through the agency of the contact person set out above, at 13:30 CET on October 29, 2020.

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Tags:

About Us

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Subscribe

Documents & Links